Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adverse event trajectories and treatment discontinuation in advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel.

Parkinsonism & related disorders·2026
Same author

Heterogeneous trajectories of executive function in clinical Alzheimer's disease: Results from the 3C study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same author

Methodological approaches to account for assay changes in longitudinal biomarker analysis: insights from Alzheimer's blood biomarkers in the MEMENTO cohort.

Alzheimer's research & therapy·2026
Same author

Development and Validation of the 3PDQ: A Self-Reported Questionnaire for Diagnosing Primary Pain in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Jul 2, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K

Recent Advances in Clinical Trials in Multiple System Atrophy.

David Bendetowicz1,2, Margherita Fabbri3,4, Federico Sirna5

  • 1Univ. Bordeaux, CNRS, IMN, UMR5293, Bordeaux, France. david.bendetowicz@u-bordeaux.fr.

Current Neurology and Neuroscience Reports
|February 28, 2024
PubMed
Summary
This summary is machine-generated.

Clinical trials for multiple system atrophy (MSA) show a robust pipeline but limited success. Future neuroprotection strategies require improved understanding of disease mechanisms and trial designs for this rare neurodegenerative disease.

Keywords:
Alpha-synucleinClinical trialsDisease-modifying therapiesMultiple system atrophy

More Related Videos

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.1K

Related Experiment Videos

Last Updated: Jul 2, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.1K

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Pharmacology

Background:

  • Multiple system atrophy (MSA) is a rare, fatal neurodegenerative disease.
  • It presents with parkinsonism, cerebellar, and autonomic dysfunction.
  • Current research focuses on neuroprotection strategies.

Purpose of the Study:

  • To review past and ongoing neuroprotection trials in MSA.
  • To describe the preclinical therapeutic pipeline for MSA.
  • To identify considerations for successful clinical trials in MSA.

Main Methods:

  • Literature review of neuroprotection trials in MSA.
  • Analysis of preclinical therapeutic pipelines.
  • Discussion of clinical trial design elements (diagnosis, endpoints).

Main Results:

  • Over 30 compounds have been tested in MSA clinical trials.
  • Only two compounds have met their primary endpoints.
  • Ongoing trials target alpha-synuclein, the hallmark of MSA.

Conclusions:

  • Despite a strong treatment pipeline, trial outcomes have been largely negative.
  • Improved understanding of disease mechanisms and preclinical models is crucial.
  • Refined clinical tools, statistical methods, and biomarkers will enhance future trial success.